Epigenomics to Launch IVD for Early Detection of Colorectal Cancer in US and Europe in 4Q

The Berlin-based company is planning to market the test in Germany, Switzerland, and Austria. Epigenomics will partner with distributors Abbott Molecular and Quest Diagnostics to launch the test in other European countries, as well as the US.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.